The US Food and Drug Administration has granted approval to the first treatment in a new drug class for a nerve condition that affects about 50,000 people worldwide.
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
Shaina M. Willen, MD, pediatric hematologist at the Vanderbilt University Medical Center, discusses the recent FDA approval of L-glutamine oral powder for sickle cell disease - the first FDA-approved...
